目的 探討血脂康膠囊聯(lián)合普伐他汀鈉片治療慢性心力衰竭的臨床療效。方法 選取2020年6月—2022年2月在天津市第三中心醫(yī)院分院就診的78例慢性心力衰竭患者，根據(jù)隨機(jī)數(shù)字表法將78例患者分為對(duì)照組和治療組，每組各39例。對(duì)照組口服普伐他汀鈉片，20 mg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服血脂康膠囊，2粒/次，2次/d。兩組患者連續(xù)治療1個(gè)月。觀察兩組的臨床療效，比較兩組心功能指標(biāo)、生活質(zhì)量和血清N末端B型利鈉肽原（NT-ProBNP）、白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）水平。結(jié)果 治療后，治療組的總有效率為92.31%，顯著高于對(duì)照組的總有效率74.36%，差異有顯著性（P＜0.05）。治療后，兩組的左室射血分?jǐn)?shù)（LVEF）、心輸出量（CO）明顯增加，左心室收縮末期內(nèi)徑（LVESD）明顯減少（P＜0.05）；治療后治療組的LVEF、CO比對(duì)照組高，LVESD比對(duì)照組低（P＜0.05）。治療后，兩組的明尼蘇達(dá)生活質(zhì)量量表（MLHFQ）評(píng)分較治療前明顯降低（P＜0.05），并且治療組患者M(jìn)LHFQ評(píng)分明顯低于對(duì)照組（P＜0.05）。治療后，兩組的血清NT-ProBNP、IL-6、TNF-α水平較治療前降低（P＜0.05），且治療組的血清NT-ProBNP、IL-6、TNF-α水平均低于對(duì)照組（P＜0.05）。結(jié)論 血脂康膠囊聯(lián)合普伐他汀鈉片治療慢性心力衰竭的療效確切，能改善患者心功能和生活質(zhì)量，降低炎癥反應(yīng)，降低心肌損傷，并且藥物安全性較好。

Objective To investigate the efficacy of Xuezhikang Capsules combined with Pravastatin Sodium Tablets in treatment of chronic heart failure.Methods Patients (78 cases) with chronic heart failure in the Branch of Tianjin Third Central Hospital from June 2020 to February 2022 were divided into control and treatment groups according to the random number table method,and each group had 39 cases.Patients in the control group were po administered with Pravastatin Sodium Tablets,20 mg/time,once daily.Patients in the treatment group were po administered with Xuezhikang Capsules on the basis of the control group,2 grains/time,twice daily.Patients in two groups were treated for 1 month.After treatment,the clinical efficacies were evaluated,and the cardiac function index,the quality of life,and the serum levels of NT-ProBNP,IL-6,and TNF-α in two groups were compared.Results After treatment,the total effective rate of the treatment group was 92.31%,which was significantly higher than 74.36% of the control group (P<0.05).After treatment,the LVEF and CO in two groups were significantly increased,but the LVESD in two groups were significantly decreased (P<0.05).After treatment,the LVEF and CO in the treatment group were higher than those in the control group,but the LVESD in the treatment group was lower than those in the control group (P<0.05).After treatment,the MLHFQ score of two groups was significantly lower than that before treatment (P<0.05),and the MLHFQ score of the treatment group was significantly lower than that of the control group (P<0.05).After treatment,the levels of NT-ProBNP,IL-6,and TNF-α in two groups were lower than those before treatment (P<0.05),and the levels of NT-ProBNP,IL-6,and TNF-α in the treatment group were lower than those in the control group (P<0.05).Conclusion Xuezhikang Capsules combined with Pravastatin Sodium Tablets has clinical curative effect in treatment of chronic heart failure,can improve patients'cardiac function and quality of life,reduce inflammatory reaction,reduce myocardial injury,with good safety.

R972